Advances in the development of cancer immunotherapies

Trends in Immunology

Volumn 34, Issue 2, 2013, Pages 90-98

  Gao, Jianjun ^a   Bernatchez, Chantale ^a   Sharma, Padmanee ^a   Radvanyi, Laszlo G ^a   Hwu, Patrick ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD134 ANTIGEN; CD19 ANTIGEN; CD40 ANTIGEN; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACARBAZINE; FLUDARABINE; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 7; IPILIMUMAB; KEYHOLE LIMPET HEMOCYANIN; LYMPHOCYTE ANTIGEN RECEPTOR; NIVOLUMAB; PEPTIDE VACCINE; PROGRAMMED DEATH 1 LIGAND 1; SIPULEUCEL T; TUMOR ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ADVANCED CANCER; ANTIBODY TITER; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL CYCLE ARREST; CELL SURVIVAL; COLORECTAL CANCER; DENDRITIC CELL; DISEASE FREE SURVIVAL; DRUG MEGADOSE; ENDOTHELIUM CELL; FOLLICULAR L; GENE MUTATION; GROWTH; HUMAN; KIDNEY C; LUNG NON SMALL CELL CANCER; LYMPHOCYTE MIGRATION; MELANOMA ME; MELANOMA METASTASIS; METASTATIC MELANOMA; NATURAL KILLER CELL; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; TUMOR REGRESSION; WHOLE BODY RADIATION;

ANIMALS; ANTIBODIES; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; NEOPLASMS; T-LYMPHOCYTES;

EID: 84873124622     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2012.08.004     Document Type: Review

References (136)

1. Caram M.V., Schuetze S.M. Advanced or metastatic gastrointestinal stromal tumors: systemic treatment options. J. Surg. Oncol. 2011, 104:888-895.
2. Smalley K.S., McArthur G.A. The current state of targeted therapy in melanoma: this time it's personal. Semin. Oncol. 2012, 39:204-214.
3. Kantoff P.W., et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 2010, 363:411-422.
4. Schuster S.J., et al. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J. Clin. Oncol. 2011, 29:2787-2794.
5. Schwartzentruber D.J., et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N. Engl. J. Med. 2011, 364:2119-2127.
6. Chang B.A., et al. Topical resiquimod promotes priming of CTL to parenteral antigens. Vaccine 2009, 27:5791-5799.
7. Marshall N.A., et al. Immunotherapy with PI3K inhibitor and Toll-like receptor agonist induces IFN-gamma+IL-17+ polyfunctional T cells that mediate rejection of murine tumors. Cancer Res. 2012, 72:581-591.
8. Kenter G.G., et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N. Engl. J. Med. 2009, 361:1838-1847.
9. Sikora A.G., et al. IFN-alpha enhances peptide vaccine-induced CD8+ T cell numbers, effector function, and antitumor activity. J. Immunol. 2009, 182:7398-7407.
10. Peggs K.S., et al. Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists. Clin. Exp. Immunol. 2009, 157:9-19.
11. Fonsatti E., et al. Biology and clinical applications of CD40 in cancer treatment. Semin. Oncol. 2010, 37:517-523.
12. Ngiow S.F., et al. Anti-TIM3 antibody promotes T cell IFN-gamma-mediated antitumor immunity and suppresses established tumors. Cancer Res. 2011, 71:3540-3551.
13. Wang L., et al. VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J. Exp. Med. 2011, 208:577-592.
14. Sedy J.R., et al. B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator. Nat. Immunol. 2005, 6:90-98.
15. Goldberg M.V., Drake C.G. LAG-3 in cancer immunotherapy. Curr. Top. Microbiol. Immunol. 2011, 344:269-278.
16. Sierro S., et al. The CD4-like molecule LAG-3, biology and therapeutic applications. Expert Opin. Ther. Targets 2011, 15:91-101.
17. Leach D.R., et al. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996, 271:1734-1736.
18. Watts T.H. TNF/TNFR family members in costimulation of T cell responses. Annu. Rev. Immunol. 2005, 23:23-68.
19. Myers L., et al. Combined CD137 (4-1BB) and adjuvant therapy generates a developing pool of peptide-specific CD8 memory T cells. Int. Immunol. 2006, 18:325-333.
20. Morris G.P., et al. CD137 signaling interferes with activation and function of CD4+CD25+ regulatory T cells in induced tolerance to experimental autoimmune thyroiditis. Cell. Immunol. 2003, 226:20-29.
21. Robertson S.J., et al. CD137 costimulation of CD8+ T cells confers resistance to suppression by virus-induced regulatory T cells. J. Immunol. 2008, 180:5267-5274.
22. Melero I., et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat. Med. 1997, 3:682-685.
23. Miller R.E., et al. 4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner. J. Immunol. 2002, 169:1792-1800.
24. Wilcox R.A., et al. Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J. Clin. Invest. 2002, 109:651-659.
25. Ito F., et al. Anti-CD137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell-based vaccines. Cancer Res. 2004, 64:8411-8419.
26. Molckovsky A., Siu L.L. First-in-class, first-in-human phase I results of targeted agents: highlights of the 2008 American society of clinical oncology meeting. J. Hematol. Oncol. 2008, 1:20.
27. Croft M. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity?. Nat. Rev. Immunol. 2003, 3:609-620.
28. Bansal-Pakala P., et al. Signaling through OX40 (CD134) breaks peripheral T-cell tolerance. Nat. Med. 2001, 7:907-912.
29. Bansal-Pakala P., et al. Costimulation of CD8 T cell responses by OX40. J. Immunol. 2004, 172:4821-4825.
30. Dawicki W., et al. 4-1BB and OX40 act independently to facilitate robust CD8 and CD4 recall responses. J. Immunol. 2004, 173:5944-5951.
31. Mousavi S.F., et al. OX40 costimulatory signals potentiate the memory commitment of effector CD8+ T cells. J. Immunol. 2008, 181:5990-6001.
32. Takeda I., et al. Distinct roles for the OX40-OX40 ligand interaction in regulatory and nonregulatory T cells. J. Immunol. 2004, 172:3580-3589.
33. Valzasina B., et al. Triggering of OX40 (CD134) on CD4(+)CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR. Blood 2005, 105:2845-2851.
34. So T., Croft M. Cutting edge: OX40 inhibits TGF-beta- and antigen-driven conversion of naive CD4 T cells into CD25+Foxp3+ T cells. J. Immunol. 2007, 179:1427-1430.
35. Vu M.D., et al. OX40 costimulation turns off Foxp3+ Tregs. Blood 2007, 110:2501-2510.
36. Weinberg A.D., et al. Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J. Immunol. 2000, 164:2160-2169.
37. Lee S.J., et al. 4-1BB and OX40 dual costimulation synergistically stimulate primary specific CD8 T cells for robust effector function. J. Immunol. 2004, 173:3002-3012.
38. Murata S., et al. OX40 costimulation synergizes with GM-CSF whole-cell vaccination to overcome established CD8+ T cell tolerance to an endogenous tumor antigen. J. Immunol. 2006, 176:974-983.
39. Lee S.J., et al. CD134 Costimulation couples the CD137 pathway to induce production of supereffector CD8 T cells that become IL-7 dependent. J. Immunol. 2007, 179:2203-2214.
40. Gri G., et al. OX40 ligand-transduced tumor cell vaccine synergizes with GM-CSF and requires CD40-Apc signaling to boost the host T cell antitumor response. J. Immunol. 2003, 170:99-106.
41. Nocentini G., et al. A new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T cell receptor-induced apoptosis. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:6216-6221.
42. Yu K.Y., et al. A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis. J. Biol. Chem. 1999, 274:13733-13736.
43. McHugh R.S., et al. CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 2002, 16:311-323.
44. Kanamaru F., et al. Costimulation via glucocorticoid-induced TNF receptor in both conventional and CD25+ regulatory CD4+ T cells. J. Immunol. 2004, 172:7306-7314.
45. Tone M., et al. Mouse glucocorticoid-induced tumor necrosis factor receptor ligand is costimulatory for T cells. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:15059-15064.
46. Shimizu J., et al. Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat. Immunol. 2002, 3:135-142.
47. Ji H.B., et al. Cutting edge: the natural ligand for glucocorticoid-induced TNF receptor-related protein abrogates regulatory T cell suppression. J. Immunol. 2004, 172:5823-5827.
48. Stephens G.L., et al. Engagement of glucocorticoid-induced TNFR family-related receptor on effector T cells by its ligand mediates resistance to suppression by CD4+CD25+ T cells. J. Immunol. 2004, 173:5008-5020.
49. Cohen A.D., et al. Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation. PLoS ONE 2010, 5:e10436.
50. Mitsui J., et al. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals. Clin. Cancer Res. 2010, 16:2781-2791.
51. Coe D., et al. Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy. Cancer Immunol. Immunother. 2010, 59:1367-1377.
52. Ko K., et al. Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells. J. Exp. Med. 2005, 202:885-891.
53. Zhou P., et al. Pivotal roles of CD4+ effector T cells in mediating agonistic anti-GITR mAb-induced-immune activation and tumor immunity in CT26 tumors. J. Immunol. 2007, 179:7365-7375.
54. Cohen A.D., et al. Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity. Cancer Res. 2006, 66:4904-4912.
55. Ko H.J., et al. A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model. Cancer Res. 2007, 67:7477-7486.
56. Beatty G.L., et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011, 331:1612-1616.
57. Vonderheide R.H., et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J. Clin. Oncol. 2007, 25:876-883.
58. Ruter J., et al. Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors. Cancer Biol. Ther. 2010, 10:983-993.
59. Liakou C.I., et al. CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:14987-14992.
60. Chen H., et al. Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:2729-2734.
61. Carthon B.C., et al. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin. Cancer Res. 2010, 16:2861-2871.
62. Vonderheide R.H., et al. Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells. Clin. Cancer Res. 2010, 16:3485-3494.
63. Yuan J., et al. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:20410-20415.
64. Korman A.J., et al. Checkpoint blockade in cancer immunotherapy. Adv. Immunol. 2006, 90:297-339.
65. Peggs K.S., et al. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy. Immunol. Rev. 2008, 224:141-165.
66. Callahan M.K., et al. Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Semin. Oncol. 2010, 37:473-484.
67. Wolchok J.D., et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010, 11:155-164.
68. Hodi F.S., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010, 363:711-723.
69. Robert C., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 2011, 364:2517-2526.
70. Keir M.E., et al. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 2008, 26:677-704.
71. Nishimura H., et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999, 11:141-151.
72. Nishimura H., et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 2001, 291:319-322.
73. Iwai Y., et al. PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int. Immunol. 2005, 17:133-144.
74. Nomi T., et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin. Cancer Res. 2007, 13:2151-2157.
75. Iwai Y., et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:12293-12297.
76. Brahmer J.R., et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 2010, 28:3167-3175.
77. Topalian S.L., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 2012, 366:2443-2454.
78. Brahmer J.R., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 2012, 366:2455-2465.
79. Khammari A., et al. Treatment of metastatic melanoma with autologous Melan-A/MART-1-specific cytotoxic T lymphocyte clones. J. Invest. Dermatol. 2009, 129:2835-2842.
80. Yee C., et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:16168-16173.
81. Dudley M.E., et al. A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J. Immunother. 2002, 25:243-251.
82. Mackensen A., et al. Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma. J. Clin. Oncol. 2006, 24:5060-5069.
83. Hunder N.N., et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N. Engl. J. Med. 2008, 358:2698-2703.
84. Rosenberg S.A., et al. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986, 233:1318-1321.
85. Dudley M.E., et al. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J. Immunother. 2003, 26:332-342.
86. Robbins P.F., et al. A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J. Exp. Med. 1996, 183:1185-1192.
87. Galon J., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313:1960-1964.
88. Bogunovic D., et al. Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:20429-20434.
89. Kilic A., et al. Density of tumor-infiltrating lymphocytes correlates with disease recurrence and survival in patients with large non-small-cell lung cancer tumors. J. Surg. Res. 2011, 167:207-210.
90. Topalian S.L., et al. Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J. Immunol. Methods 1987, 102:127-141.
91. Junker N., et al. Bimodal ex vivo expansion of T cells from patients with head and neck squamous cell carcinoma: a prerequisite for adoptive cell transfer. Cytotherapy 2011, 13:822-834.
92. Rosenberg S.A., et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J. Natl. Cancer Inst. 1994, 86:1159-1166.
93. Dudley M.E., et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 2005, 23:2346-2357.
94. Besser M.J., et al. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin. Cancer Res. 2010, 16:2646-2655.
95. Dudley M.E., et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 2008, 26:5233-5239.
96. Rosenberg S.A., et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 2011, 17:4550-4557.
97. Zhou J., et al. Selective growth, in vitro and in vivo, of individual T cell clones from tumor-infiltrating lymphocytes obtained from patients with melanoma. J. Immunol. 2004, 173:7622-7629.
98. Rosenberg S.A., et al. Gene transfer into humans-immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N. Engl. J. Med. 1990, 323:570-578.
99. Kline J., et al. Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma. Clin. Cancer Res. 2008, 14:3156-3167.
100. Yao X., et al. Levels of peripheral CD4+FoxP3+ regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer. Blood 2012, 119:5688-5696.
101. Angulo I., et al. Nitric oxide-producing CD11b(+)Ly-6G(Gr-1)(+)CD31(ER-MP12)(+) cells in the spleen of cyclophosphamide-treated mice: implications for T-cell responses in immunosuppressed mice. Blood 2000, 95:212-220.
102. Johnson L.A., et al. Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes. J. Immunol. 2006, 177:6548-6559.
103. Johnson L.A., et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009, 114:535-546.
104. Parkhurst M.R., et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol. Ther. 2011, 19:620-626.
105. Robbins P.F., et al. Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions. J. Immunol. 2008, 180:6116-6131.
106. Robbins P.F., et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 2011, 29:917-924.
107. Provasi E., et al. Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nat. Med. 2012, 18:807-815.
108. Yun C.O., et al. Targeting of T lymphocytes to melanoma cells through chimeric anti-GD3 immunoglobulin T-cell receptors. Neoplasia 2000, 2:449-459.
109. Hwu P., et al. Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain. J. Exp. Med. 1993, 178:361-366.
110. Till B.G., et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 2008, 112:2261-2271.
111. Kershaw M.H., et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 2006, 12:6106-6115.
112. Jensen M.C., et al. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol. Blood Marrow Transplant. 2010, 16:1245-1256.
113. Haynes N.M., et al. Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. Blood 2002, 100:3155-3163.
114. Maher J., et al. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor. Nat. Biotechnol. 2002, 20:70-75.
115. Lo A.S., et al. Anti-GD3 chimeric sFv-CD28/T-cell receptor zeta designer T cells for treatment of metastatic melanoma and other neuroectodermal tumors. Clin. Cancer Res. 2010, 16:2769-2780.
116. Sadelain M., et al. The promise and potential pitfalls of chimeric antigen receptors. Curr. Opin. Immunol. 2009, 21:215-223.
117. Wilkie S., et al. Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor. J. Immunol. 2008, 180:4901-4909.
118. Porter D.L., et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 2011, 365:725-733.
119. Kochenderfer J.N., et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010, 116:4099-4102.
120. Ertl H.C., et al. Considerations for the clinical application of chimeric antigen receptor T cells: observations from a recombinant DNA Advisory Committee Symposium held June 15, 2010. Cancer Res. 2011, 71:3175-3181.
121. Brentjens R., et al. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol. Ther. 2010, 18:666-668.
122. Morgan R.A., et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 2010, 18:843-851.
123. Di Stasi A., et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 2011, 365:1673-1683.
124. Sjoblom T., et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006, 314:268-274.
125. Segal N.H., et al. Epitope landscape in breast and colorectal cancer. Cancer Res. 2008, 68:889-892.
126. Peggs K.S., et al. Targeting immunosupportive cancer therapies: accentuate the positive, eliminate the negative. Cancer Cell 2007, 12:192-199.
127. Wilmott J.S., et al. Selective BRAF inhibitors induce marked T cell infiltration into human metastatic melanoma. Clin. Cancer Res. 2011, 18:1386-1394.
128. Kvistborg P., et al. TIL therapy broadens the tumor-reactive CD8+ T cell compartment in melanoma patients. Oncoimmunology 2012, 1:409-418.
129. Andersen R.S., et al. Dissection of T-cell antigen specificity in human melanoma. Cancer Res. 2012, 72:1642-1650.
130. Matsushita H., et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 2012, 482:400-404.
131. Bronte V., et al. L-arginine metabolism in myeloid cells controls T-lymphocyte functions. Trends Immunol. 2003, 24:302-306.
132. Munn D.H. Blocking IDO activity to enhance anti-tumor immunity. Front. Biosci. 2012, 4:734-745.
133. Lee S.Y., et al. The immune tolerance of cancer is mediated by IDO that is inhibited by COX-2 inhibitors through regulatory T cells. J. Immunother. 2009, 32:22-28.
134. Basu G.D., et al. Cyclooxygenase-2 inhibitor enhances the efficacy of a breast cancer vaccine: role of IDO. J. Immunol. 2006, 177:2391-2402.
135. Sitkovsky M.V., et al. Hypoxia-adenosinergic immunosuppression: tumor protection by T regulatory cells and cancerous tissue hypoxia. Clin. Cancer Res. 2008, 14:5947-5952.
136. Yang L., et al. TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol. 2010, 31:220-227.